Microbicides—and women—scored big this morning when Bristol-Myers Squibb and Merck announced separate licensing agreements with the International Partnership for Microbicides todevelop a gel or cream that protects women against HIV. Topical entry-inhibitors developed by both companies recently did well in studies on monkeys.